216 related articles for article (PubMed ID: 15731291)
1. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Gossec L; van der Heijde D; Melian A; Krupa DA; James MK; Cavanaugh PF; Reicin AS; Dougados M
Ann Rheum Dis; 2005 Nov; 64(11):1563-7. PubMed ID: 15731291
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
van der Heijde D; Baraf HS; Ramos-Remus C; Calin A; Weaver AL; Schiff M; James M; Markind JE; Reicin AS; Melian A; Dougados M
Arthritis Rheum; 2005 Apr; 52(4):1205-15. PubMed ID: 15818702
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
[TBL] [Abstract][Full Text] [Related]
4. Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis.
Lee W; Weisman MH
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):298-9. PubMed ID: 16932706
[No Abstract] [Full Text] [Related]
5. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
Balazcs E; Sieper J; Bickham K; Mehta A; Frontera N; Stryszak P; Popmihajlov Z; Peloso PM
BMC Musculoskelet Disord; 2016 Oct; 17(1):426. PubMed ID: 27737664
[TBL] [Abstract][Full Text] [Related]
6. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Reginster JY; Malmstrom K; Mehta A; Bergman G; Ko AT; Curtis SP; Reicin AS
Ann Rheum Dis; 2007 Jul; 66(7):945-51. PubMed ID: 17142385
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.
Peloso PM; Gammaitoni A; Smugar SS; Wang H; Moore AR
BMC Musculoskelet Disord; 2011 Jul; 12():165. PubMed ID: 21767407
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
Malmstrom K; Kotey P; Coughlin H; Desjardins PJ
Clin J Pain; 2004; 20(3):147-55. PubMed ID: 15100590
[TBL] [Abstract][Full Text] [Related]
11. Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial.
Matsumoto A; Melian A; Shah A; Curtis SP
Curr Med Res Opin; 2007 Sep; 23(9):2259-68. PubMed ID: 17697449
[TBL] [Abstract][Full Text] [Related]
12. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Am J Gastroenterol; 2006 Feb; 101(2):311-7. PubMed ID: 16454836
[TBL] [Abstract][Full Text] [Related]
13. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
14. Association between health-related quality of life and clinical efficacy endpoints in rheumatoid arthritis patients after four weeks treatment with anti-inflammatory agents.
Eichler HG; Mavros P; Geling O; Hunsche E; Kong S
Int J Clin Pharmacol Ther; 2005 May; 43(5):209-16. PubMed ID: 15906586
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H
Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
17. Etoricoxib.
Cochrane DJ; Jarvis B; Keating GM
Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
[TBL] [Abstract][Full Text] [Related]
18. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.
Schumacher HR; Boice JA; Daikh DI; Mukhopadhyay S; Malmstrom K; Ng J; Tate GA; Molina J
BMJ; 2002 Jun; 324(7352):1488-92. PubMed ID: 12077033
[TBL] [Abstract][Full Text] [Related]
19. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.
Wiesenhutter CW; Boice JA; Ko A; Sheldon EA; Murphy FT; Wittmer BA; Aversano ML; Reicin AS;
Mayo Clin Proc; 2005 Apr; 80(4):470-9. PubMed ID: 15819283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
